Mural Oncology PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Mural Oncology plc Director Benjamin Hickey's stock options were cancelled without consideration following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc's CEO, Caroline Loew, disposed of her beneficial ownership in ordinary shares and stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc director Francis M. Cuss reports the cancellation of stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc director Scott Thomas Jackson's stock options were cancelled following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc has been acquired by XRA 5 Corp. for $2.035 per share, resulting in the cancellation of certain stock options without consideration.
Mural Oncology plc director Sachiyo Minegishi's stock options were cancelled without consideration following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology, disposed of all her ordinary shares and stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc's Chief Medical Officer, Vicki L. Goodman, reported changes in her beneficial ownership following the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology plc's CFO, Adam D. Cutler, disposed of ordinary shares and restricted stock units as part of the company's acquisition by XRA 5 Corp. for $2.035 per share.
Mural Oncology's Chief Financial Officer, Adam D. Cutler, sold 7,148 ordinary shares at $2.09 each to cover tax withholding obligations related to restricted stock unit vesting.
Mural Oncology's Chief Medical Officer, Vicki L. Goodman, sold 5,036 ordinary shares at $2.08 each to cover tax withholding obligations related to vested restricted stock units.
Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology plc, sold 2,572 ordinary shares for a weighted average price of $2.48 per share under a pre-arranged 10b5-1 trading plan.
Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology plc, sold 2,158 ordinary shares at $2.48 each to cover tax withholding obligations related to vested restricted stock units.
Mural Oncology plc's CEO, Caroline Loew, sold 12,531 ordinary shares on July 7, 2025, at a weighted average price of $2.432 per share to satisfy tax withholding obligations related to vested restricted stock units.
Mural Oncology plc (MURA) has reported that Director Francis M. Cuss was granted 8,637 stock options with an exercise price of $2.56, aligning his interests with shareholder value.
Mural Oncology plc's Director, Sachiyo Minegishi, was granted 8,637 stock options with an exercise price of $2.56, vesting upon the earlier of the first anniversary of the grant or the next Annual Meeting.
Mural Oncology plc's Director, Scott Thomas Jackson, has been granted 8,637 stock options with an exercise price of $2.56, aligning his interests with the company's performance.
Mural Oncology plc's Director, George Golumbeski, was granted 8,637 stock options with an exercise price of $2.56, vesting over one year or upon the next Annual Meeting.
Mural Oncology plc's Director, Benjamin Hickey, was granted 8,637 stock options with an exercise price of $2.56, aligning his interests with the company's long-term performance.
Maiken Keson-Brookes, Chief Legal Officer of Mural Oncology, reports acquisition of restricted stock units and stock options, as well as sales of ordinary shares to cover tax obligations.
Caroline Loew, CEO of Mural Oncology plc, reports the acquisition of shares through restricted stock units and stock options, as well as the disposal of shares to cover tax obligations.
Vicki L. Goodman, Chief Medical Officer of Mural Oncology plc, reports the acquisition of ordinary shares and stock options, as well as the disposal of shares.
Adam Cutler, CFO of Mural Oncology plc, reports the acquisition of 35,000 ordinary shares and 65,000 stock options.
Vicki L. Goodman, Chief Medical Officer of Mural Oncology plc, reports the sale of 13,186 ordinary shares under a pre-arranged Rule 10b5-1 trading plan.
Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology, sold 2,555 ordinary shares at an average price of $3.27 under a pre-arranged 10b5-1 trading plan.
Mural Oncology's CEO, Caroline Loew, sold 2,763 shares to cover tax obligations related to vesting restricted stock units.
Vicki L Goodman, Chief Medical Officer of Mural Oncology plc, sold 5,069 ordinary shares to satisfy withholding obligations related to vesting restricted stock units.
Adam Cutler, CFO of Mural Oncology plc, reported the sale of 7,421 ordinary shares to cover withholding obligations related to vesting restricted stock units.
Director Sachiyo Minegishi of Mural Oncology plc reports the acquisition of stock options.
Director Susan Altschuller purchased 10,000 ordinary shares of Mural Oncology plc at a weighted average price of $3.2071 on August 14, 2024.